Similar Tolerance of Glucagon‐Like PEPTIDE‐1 Agonist Therapy in Patients With Delayed and Normal Gastric Emptying
Neurogastroenterology & Motility · 2026-11 · 38 (11)
DOI: 10.1111/nmo.70448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurogastroenterology & Motility, online erschienen am 05.11.2026. Verfasst von Stacey C Rolak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA. Hauptthemen laut MEDLINE: Gastric Emptying, Gastroparesis, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Introduction
Gastroparesis is considered a relative contraindication to glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) prescription. We examined outcomes of patients who underwent gastric scintigraphy to determine if emptying delays adversely affected tolerance of subsequent GLP‐1RA therapy.
Methods
Patients with delayed (DGE) and normal (NGE) gastric emptying who were subsequently prescribed GLP‐1RAs were identified. GLP‐1RA prescribing profiles, gastrointestinal (GI) symptoms and treatments, and GLP‐1RA discontinuation were compared between patients with DGE versus NGE. Key Results Eighty‐one patients were prescribed GLP‐1RAs after scintigraphy; 14/81 (17%) with DGE and 67/81 (83%) with NGE. Injectable semaglutide was most often prescribed and was taken at similar doses for DGE (11/14, 79%) and NGE (40/67, 60%) ( p = 0.23). GLP‐1RAs were initiated a median of 386 days (IQR 190, 474) after scintigraphy with DGE versus 315 days (IQR 157, 613) with NGE ( p = 0.86). GI symptoms developed in 5/14 (36%) with DGE versus 35/67 (52%) with NGE ( p = 0.38) and antiemetic ( p = 0.75) and prokinetic ( p = 1.00) use was similar between groups. GLP‐1RAs were discontinued in 45/81 (56%) patients including 14/45 (31%) for GI symptoms, which occurred similarly for DGE (3/8, 38%) and NGE (11/37, 30%) ( p = 0.70). Treatment durations were similar with DGE (318 days [IQR 223, 464]) versus NGE (193 days [IQR 83, 363]) ( p = 0.31). Conclusions and Inferences GLP‐1RAs are taken at similar doses for similar durations, elicit similar symptoms, and are discontinued for similar reasons in patients with prior delayed versus normal gastric emptying. These observations do not support strictly avoiding GlP‐1RAs in gastroparesis and suggest they may be safely prescribed in many cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
- Division of Nuclear Medicine, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
ORCID-Profile: Stacey C Rolak, Tisha N Lunsford, Lucinda A Harris, Ming Yang, William L Hasler
Zitieren
APA
Rolak, S. C., Lunsford, T. N., Frazier, R. D., Harris, L. A., Yang, M., & Hasler, W. L. (2026). Similar Tolerance of Glucagon‐Like PEPTIDE‐1 Agonist Therapy in Patients With Delayed and Normal Gastric Emptying. Neurogastroenterology & Motility, 38(11). https://doi.org/10.1111/nmo.70448
Vancouver
Rolak SC, Lunsford TN, Frazier RD, Harris LA, Yang M, Hasler WL. Similar Tolerance of Glucagon‐Like PEPTIDE‐1 Agonist Therapy in Patients With Delayed and Normal Gastric Emptying. Neurogastroenterology & Motility. 2026;38(11). doi:10.1111/nmo.70448
BibTeX
@article{Rolak2026,
author = {Rolak, Stacey C and Lunsford, Tisha N and Frazier, Rosita D and Harris, Lucinda A and Yang, Ming and Hasler, William L},
title = {Similar Tolerance of Glucagon‐Like PEPTIDE‐1 Agonist Therapy in Patients With Delayed and Normal Gastric Emptying},
journal = {Neurogastroenterology & Motility},
year = {2026},
volume = {38},
number = {11},
doi = {10.1111/nmo.70448}
}
EUVIMED